Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958045 · ClinicalTrials.gov registry record · Phase 2
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
A Phase 2 study of Small-cell Lung Cancer, sponsored by Zhonglin Hao.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03958045 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by Zhonglin Hao. The registered enrollment target is 33 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03958045, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by Zhonglin Hao.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Rucaparib and Nivolumab
Study Locations (1)
Kentucky
- Markey Cancer Center, University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03958045
The ClinicalTrials.gov registry entry for NCT03958045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Zhonglin Hao, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Rucaparib and Nivolumab is the first listed.
NCT03958045 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03958045 about?
NCT03958045 is a clinical study titled "Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma". The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.
What is the current status of trial NCT03958045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-09-04. Estimated completion is 2022-11-15.
What conditions does trial NCT03958045 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03958045?
The interventions under investigation include: Rucaparib and Nivolumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03958045?
This trial is sponsored by Zhonglin Hao, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03958045 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.